S&P 500   3,351.28 (+0.06%)
DOW   27,433.48 (+0.17%)
QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,167.46 (-1.78%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,452.71 (-2.48%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
S&P 500   3,351.28 (+0.06%)
DOW   27,433.48 (+0.17%)
QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,167.46 (-1.78%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,452.71 (-2.48%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
S&P 500   3,351.28 (+0.06%)
DOW   27,433.48 (+0.17%)
QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,167.46 (-1.78%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,452.71 (-2.48%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
S&P 500   3,351.28 (+0.06%)
DOW   27,433.48 (+0.17%)
QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,167.46 (-1.78%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,452.71 (-2.48%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
Log in

OTCMKTS:UCBJFUCB Stock Price, Forecast & News

$127.00
0.00 (0.00 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$127.00
Now: $127.00
$127.00
50-Day Range
$114.65
MA: $122.38
$131.00
52-Week Range
$67.39
Now: $127.00
$131.00
VolumeN/A
Average Volume189 shs
Market Capitalization$24.70 billion
P/E Ratio21.82
Dividend YieldN/A
Beta0.52
UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.
Read More
UCB logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.71 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:UCBJF
CUSIPN/A
CIKN/A
Phone32-2559-9999

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.50 billion
Cash Flow$5.61 per share
Book Value$40.36 per share

Profitability

Miscellaneous

Employees7,606
Market Cap$24.70 billion
Next Earnings DateN/A
OptionableNot Optionable
$127.00
0.00 (0.00 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive UCBJF News and Ratings via Email

Sign-up to receive the latest news and ratings for UCBJF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











UCB (OTCMKTS:UCBJF) Frequently Asked Questions

How has UCB's stock been impacted by COVID-19 (Coronavirus)?

UCB's stock was trading at $97.20 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, UCBJF shares have increased by 30.7% and is now trading at $127.00.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of UCB?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for UCB in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for UCB
.

Has UCB been receiving favorable news coverage?

Media headlines about UCBJF stock have been trending very positive on Friday, according to InfoTrie. The research group scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. UCB earned a news impact score of 4.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days.
View the latest news about UCB
.

Who are some of UCB's key competitors?

Who are UCB's key executives?

UCB's management team includes the following people:
  • Jean-Christophe Tellier, Chief Executive Officer & Executive Director
  • Charl van Zyl, Chief Operating Officer
  • Detlef Thielgen, Chief Financial Officer & Executive Vice President
  • Iris Löw-Friedrich, Chief Medical Officer & Executive Vice President
  • Dhavalkumar Patel, Chief Scientific Officer & EVP

What is UCB's stock symbol?

UCB trades on the OTCMKTS under the ticker symbol "UCBJF."

How do I buy shares of UCB?

Shares of UCBJF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is UCB's stock price today?

One share of UCBJF stock can currently be purchased for approximately $127.00.

How big of a company is UCB?

UCB has a market capitalization of $24.70 billion and generates $5.50 billion in revenue each year. The company earns $887.04 million in net income (profit) each year or $5.82 on an earnings per share basis. UCB employs 7,606 workers across the globe.

What is UCB's official website?

The official website for UCB is www.ucb.com.

How can I contact UCB?

UCB's mailing address is Allee de la Recherche 60, Brussels C9, 1070. The company can be reached via phone at 32-2559-9999 or via email at [email protected]

This page was last updated on 8/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.